Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Polomar Health ServicesPMHS 37 Debt-to-EBITDA is 0.87 as of Jun. 2026. GuruFocus rates PMHS with a GF Score™ of 37/100 and a GF Value™ of $23.25 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 480 Healthcare Providers & Services companies, Polomar Health Services ranks worse than 208333.13% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Polomar Health Services's Debt-to-EBITDA or its related term are showing as below:
PMHS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -9.24 Med: -1.15 Max: -0.14
Current: -9.24
During the past 7 years, the highest Debt-to-EBITDA Ratio of Polomar Health Services was -0.14. The lowest was -9.24. And the median was -1.15.
PMHS's Debt-to-EBITDA is ranked worse than 100% of 480
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs PMHS: -9.24
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Polomar Health Services Debt-to-EBITDA Related Terms
Polomar Health Services Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMHS vs DHTI, RDGT, BLMH: Debt-to-EBITDA Comparison
For the Pharmaceutical Retailers subindustry, Polomar Health Services's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polomar Health Services Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Polomar Health Services's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Polomar Health Services's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Polomar Health Services (PMHS) has a Debt-to-EBITDA of 0.87 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Polomar Health Services. According to the industry distribution chart, Polomar Health Services ranks #999999 out of 480 companies in the Healthcare Providers & Services industry.
Is Polomar Health Services' Debt-to-EBITDA too high?
Polomar Health Services' current Debt-to-EBITDA is 0.87. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. Polomar Health Services' value of 0.87 is 60.2% below this industry median. Based on the distribution chart, Polomar Health Services ranks #999999 out of 480 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Polomar Health Services has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Polomar Health Services' Debt-to-EBITDA compare to DHTI and RDGT?
According to the Healthcare Providers & Services industry distribution chart, Polomar Health Services ranks #999999 out of 480 companies for Debt-to-EBITDA. This places Polomar Health Services in the lower half of its industry. The industry median Debt-to-EBITDA is 2.19. Polomar Health Services' value of 0.87 is 60.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 480 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polomar Health Services's current Debt-to-EBITDA of 0.87 is 60.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Polomar Health Services. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polomar Health Services's current Debt-to-EBITDA is 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polomar Health Services stock overvalued right now?
Based on GuruFocus' analysis, Polomar Health Services (PMHS) is currently considered Possible Value Trap. The stock's GF Value™ is $23.25, compared to a current price of $0.22 — trading 99.1% below its estimated fair value. The current Debt-to-EBITDA is 0.87 and 60.2% below the Healthcare Providers & Services industry median of 2.19. Polomar Health Services' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Polomar Health Services (PMHS), the current Debt-to-EBITDA is 0.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polomar Health Services (PMHS) Overvalued in 2026?
Based on GuruFocus' analysis, Polomar Health Services stock appears to be undervalued.
The current stock price of $0.22 is trading 99.1% below its estimated GF Value™ of $23.25.
GuruFocus considers Polomar Health Services to be Possible Value Trap.
Key valuation signals for PMHS:
Debt-to-EBITDA: 0.87
GF Value™: $23.25 vs. price of $0.22 (99.1% below fair value)
Industry Position: 60.2% below the Healthcare Providers & Services median (#999999 of 480)
No single metric tells the full story. See the PMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polomar Health Services Inc is a U.S.-based healthcare company specializing in retail compounding pharmacy services and prescription fulfillment for telehealth platforms. It is also licensed as a Special Sterile Compounding Pharmacy, permit #PH35277, which authorizes the licensed entity to dispense injectable and other sterile compounds (eye drops, infused therapeutics) upon receipt of a valid prescription. The firm is presently licensed and authorized to fulfill and deliver compounded prescribed medications in 28 states.
37GF Score
Get the complete analysis for PMHS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMHS has been successfully added to your 
